Cybin Inc (CYBN-NE) Stock Price and News - The Globe and Mail

TOP STORIES: Cybin Inc

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

September 23, 2025

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

September 11, 2025

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

September 8, 2025

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

September 4, 2025

Cybin to Participate in the Cantor Global Healthcare Conference 2025

September 3, 2025

Cybin Announces Senior Leadership Changes

September 2, 2025

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

August 26, 2025

Cybin Announces Results of Annual Meeting of Shareholders

August 18, 2025

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

August 13, 2025

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

Cybin to Participate in the 2025 Psychedelic Science Conference

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

Cybin Applauds FDA Commissioner Dr. Martin Makary’s Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

Cybin to Participate at the 28th Annual Milken Institute Global Conference

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs

Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

February 10, 2025

Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

January 15, 2025

Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025

January 13, 2025

Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

January 9, 2025

Profile

Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.